New executive team for Zimmer Centerpulse:
This article was originally published in Clinica
Executive Summary
Zimmer (Warsaw, Indiana) has appointed a new global executive team to lead the company's efforts regarding the recently completed acquisition of Centerpulse. In addition to Zimmer's chairman, president and CEO Ray Elliott, the team comprises Dr Cheryl Blanchard (vice-president of corporate research and clinical affairs); Sheryl Conley (president of the global products group); David Dvorak (executive vice-president of corporate services and chief counsel); David Floyd (president of Zimmer USA); Richard Fritschi (president of Zimmer USA); Sam Leno (executive vice-president of corporate finance and operations and CFO); Bruno Melzi (chairman of Zimmer International); Bruce Peterson (chairman of Zimmer Americas); and Terry Schlotterback (president of Zimmer SpineTech). Jim Crines (vice-president of finance, controller) and Chris Jefferis (vice-president of global integration) have also been appointed to the executive committee to form a broader operating committee. Another four-to-six places on the operating committee are yet to be filled.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.